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Abstract 
Background: New therapies are created to address specific problems and enjoy popularity as 
they enter widespread clinical use. Broader use can reveal unknown adverse effects and impact 
the life cycle significantly. Succinylcholine, a depolarizing neuromuscular blocker, was the 
product of decades of research surrounding the ancient compound, curare. It was introduced into 
practice in the 1940s by Burroughs Wellcome and Company (BW Co.) and was welcomed due to 
its rapidly acting muscle relaxation effects. Global clinical use revealed adverse effects, both 
minor and major, in particular, hyperkalemia and malignant hyperthermia. We investigated when 
practitioners and the manufacturer became aware of these adverse effects, how information about 
these side effects were disseminated, and whether the manufacturer met the regulatory 
requirements of the time, specifically regarding the timely reporting of adverse effects.  
Sources: Primary literature search using online and archived documents was conducted at the 
Wood Library-Museum of Anesthesiology, Schaumburg, Illinois. We consulted documents 
submitted by BW Co. to federal authorities, through the Freedom of Information Act (FOIA), 
Food and Drug Administration (FDA) reports, promotional advertisements, package inserts, 
published articles, and textbooks.  
Results: Initial clinical testing in humans in 1952 found no adverse effects on cardiovascular or 
respiratory systems. Fasciculations and myalgia were early side effects described in case reports 
in 1952. Large-scale clinical trials in 1953 found abnormally long recovery times among some 
patients; the discovery of abnormal pseudocholinesterase enzyme activity was not fully 
demonstrated until the early 1960s. Bradycardia was first reported in 1957 in children, and in 
1959 in adults. In 1960, animal studies reported a transient increase in plasma potassium; further 
experiments in 1969 clearly demonstrated succinylcholine-induced hyperkalemia in burn 
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patients. Malignant hyperthermia was first described in 1966. Similar cases of elevated 
temperatures and muscle rigidity were described globally but the underlying mechanism was not 
elucidated until the 1990s. Standard anesthesia textbooks did not report major side effects of 
succinylcholine until 1960 and included newly documented side effects with each edition. BW 
Co.'s packaging contained warnings as early as the 1950's but were later updated in 1962 and 
beyond to reflect the newly discovered hyperkalemia and malignant hyperthermia. 
Conclusion: Particularly given the regulatory environment of the time, BW Co. appropriately 
reported the adverse effects of succinylcholine after market entry; it updated promotional and 
packaging material in a timely manner to reflect newly discovered adverse effects. The toxicity, 
though alarming and put clinicians on alert, did not seem to heavily impact succinylcholine's use, 
given its various desirable properties. It is still a choice muscle relaxant used today, although 
there are efforts to develop superior agents to replace succinylcholine. 
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Introduction 
Pharmacological and nonpharmacological treatments possess a life cycle like that of 
newly introduced products in our daily lives. The novelty of a new and different drug attracts 
early adopters who are eager to test out the promised effects, after which there is a general 
acceptance by clinicians at large. Often, with broader use and off-label use, the adverse effects of 
the drug appear, with some that are predicable while others are not. Over time, enthusiasm for 
these drugs may wane as the reality of harmful side effects sets in and as investigators discover 
replacements with improved safety and efficacy, just as these drugs may have replaced earlier 
ones. These drugs disappear from the scene permanently when they are no longer 
commercialized. 
We discuss the introduction, evolution of use, identification and publicizing of side 
effects of a commonly used medication in modern anesthetic practice: succinylcholine, also 
known as suxamethonium chloride (international nonproprietary name). D-Tubocurarine had 
been introduced into clinical use in the 1930s and was extremely useful for surgical procedures 
involving the abdomen. However, its duration of action (30-60 minutes) was too long for short 
procedures such as electroconvulsive therapy, dental extraction, tracheal intubation, and 
operations of a short duration. Succinylcholine fulfilled the requirements for the aforementioned 
short procedures, and continuous infusions were used for longer procedures as well. 
As the drug was being developed for clinical use, the manufacturer, Burroughs Wellcome 
and Company (BW Co.), would have conducted investigations to determine clinical efficacy 
while also noting adverse effects. We sought to determine if clinically significant adverse 
reactions may have been evident in retrospect and should have been included in the marketing 
materials. 
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 The United States Food and Drug Administration (FDA)’s pharmaceutical approval 
process underwent numerous amendments over its existence. The 1938 Federal Food, Drug, and 
Cosmetic Act began requiring manufacturers to demonstrate product safety prior to approval for 
marketing. [1] Specific requirements by the FDA for the disclosure of risk information in 
advertising materials and promotional labeling were tied to the expansion of its authority. [2] In 
1951, Congress passed the Durham Humprey Amendment, which required that specific drugs be 
prescribed by a medical professional. This was the first time that there was a statutory definition 
of drugs based on defined criteria. A period followed in which promotional materials were 
everywhere; interestingly, the FDA did not regulate advertising in medical journals; this was the 
role of the Federal Trade Commission (FTC; Wheeler Lea Act, 1938).  In fact, claims of efficacy 
were often made despite a lack of evidence. In part because evidence for causality (particularly 
with low frequency adverse events) is best inferred from large systematic clinical trials that may 
not have been available at the time, safety was typically assumed. Thus, congressional hearings 
on pharmaceutical marketing practices ensued, accelerated by an observation in Europe that 
thalidomide was associated with serious birth defects.  
The Federal Trade Commission (FTC) is also granted oversight of advertising for FDA-
regulated materials. In the years leading up to the discovery of succinylcholine, the FDA 
developed more regulations, including guidelines of good manufacturing practices for quality 
control in 1941, banning illegal drug sales in 1948, clarification of use on drug labels in 1950, 
and the limitation of sale of drugs meant to be used by medical professionals in the 1951 
Durham-Humphrey Amendment. [3] In 1952, a voluntary program to report drug reactions was 
formed and a decade later, the Kefauver-Harris Amendments were passed in 1962, which not 
only required manufacturers to prove product efficacy through controlled clinical trials prior to 
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approval, but also to report any serious side effects after market entry. [4] These amendments 
also transferred the control of pharmaceutical advertising to the FDA. In the years that followed, 
the FDA put forth further rules to regulate clinical trials, including the Investigational New Drug 
and New Drug Application approval pathways; these required manufacturers to demonstrate new 
agents’ safety through different phases of testing, as well as approval from an Institutional 
Review Board of information pertaining to the sponsors, methods, and patients involved before 
the study was allowed to be conducted. [5] The Fair Packaging and Labeling Act of 1966 
required all products to have honest and informative labels and the FDA required package inserts 
with information about risks and benefits for all medications starting in 1970.The development 
of enhanced safety standards through the 1970s by the FDA formed the backdrop for establishing 
a legal responsibility and accountability for BW Co. in its production and marketing of 
succinylcholine. We investigate marketing material and package inserts by BW Co. for 
succinylcholine over three decades to track the updates in listed side effects.  
 
Sources 
Primary literature search was conducted at the Wood Library-Museum of 
Anesthesiology, Schaumberg, Illinois, using archived documents and online databases. Archived 
documents consisted of advertisements in early editions of anesthesia journals, physical copies of 
original research articles, case reports, drug package inserts, drug information packets, and other 
manufacturer marketing materials. We also reviewed documents submitted to the Federal Drug 
Administration (FDA) by BW Co. for approval of succinylcholine’s use in the clinical setting 
(through the Freedom of Information Act) and other FDA reports. We examined updated editions 
of anesthesia and pharmacology textbooks to ascertain when information about adverse effects 
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was published in standard medical textbooks, specifically Goodman and Gilman’s 
Pharmacological Basis of Therapeutics, Dripps/Eckenhoff/Vandam’s Introduction to 
Anesthesia, Collins’ Principles of Anesthesiology, and Wylie’s A Practice of Anaesthesia. We 
reviewed the textbooks’ sections on neuromuscular blocking agents and adverse effects, 
specifically, hyperkalemia, and malignant hyperthermia.  
 
History and Synthesis 
The history of neuromuscular blocking agents can be traced back to curare. This plant 
extract was used by aboriginal tribes in South America to hunt wild animals for centuries. Its 
notable paralytic effect on the respiratory system of animals was carried into clinical practice in 
the 1800s, when curare was used to treat tetanus. In 1856 Claude Bernard conducted detailed 
laboratory experiments to elucidate the drug’s mechanism and site of action. [6] Attempts were 
made to purify and then synthesize the compounds that gave curare its properties. This resulted 
in the isolation of d-tubocurarine by Harold King in 1935. King’s discovery prompted further 
pharmacological investigation into compounds that mimicked the structure of d-tubocurarine, 
especially its two separated quaternary groups, which were thought to be responsible for the 
neuromuscular block. [7] 
Three different groups reported the action of succinylcholine at the neuromuscular 
junction from 1949-1950: one led by Nobel-prize winner Daniel Bovet in Italy, one led by James 
Walker in the U.K., and one led by Edwin de Beer in the U.S. [8-11] It should be noted that Reid 
Hunt originally developed succinylcholine in 1906 through his studies of acetylcholine but 
conducted his experiments of succinylcholine in the presence of curare, and thus 
succinylcholine’s muscle relaxation properties went unnoticed. [12] 
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De Beer and Castillo’s report on succinylcholine in the 1950s described its 
neuromuscular blocking action in animal studies. [8] The compound was tested on cats, dogs, 
rabbits, mice, and frogs. The authors noted that the paralysis produced was on par with d-
tubocurarine’s effects, even with a very low dose succinylcholine, and marveled at its rapid onset 
and duration of the neuromuscular block. They did not observe any effects on blood pressure. 
They remarked that the action of succinylcholine could be prolonged by the administration of 
anticholinesterase inhibitors (such as physostigmine), whereas the action of d-tubocurarine was 
antagonized and nearly abolished by anticholinesterase inhibitors. These findings were consistent 
with previous observations by Bovet-Nitti. [8] At the time, Castillo’s and Bovet-Nitti’s teams 
assumed that the prolongation of action was due to physostigmine antagonizing a downstream 
enzyme that metabolized succinylcholine. Bovet’s animal studies in 1951 found that large doses 
of succinylcholine caused transient hypertension. [13] 
Succinylcholine was manufactured as an iodized salt, and also as succinylcholine 
chloride. [14, 15] The iodized salt was water soluble, but would undergo spontaneous breakdown 
over time, requiring clinicians to either dissolve it immediately prior to use or administer it 
subsequently without knowing how much active ingredient remained. [16] Moreover, patients 
allergic to iodinated products and shellfish could receive the chlorinated compound safely. [17] 
As a result, succinylcholine chloride is the form in which the drug has been manufactured ever 
since.  
 
Adverse Effects Publicized  
In 1952, Thesleff’s group in Stockholm reported that an injection of succinylcholine 
caused fasciculations initially, and these were followed by muscle paralysis in animals. 
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Fasciculations were fairly common side effect that was reported in nearly every study that 
described the use of succinylcholine. [14, 18, 19] 
Thesleff’s group also reported that doses greater than 2mg/kg caused transient increases 
in blood pressure in animals. Doses greater than 30mg/kg caused bradycardia or cardiac 
arrhythmias in animals. [14] Bradycardia wasn’t reported in human subjects until 1957, where it 
was first described in young children and infants. [20] In 1959, Bullough, commenting on a 
manuscript published in the previous year by Martin, summarized their findings on adult 
patients: bradycardia occurred following repeated administrations of succinylcholine, sometimes 
with leading to arrhythmias or cardiac arrest, recommending premedication with atropine if 
repeated dosing was required. [21] 
Initial clinical testing on over 1,000 patients reported no effects on blood pressure, pulse, 
or salivation, no bronchospasm, and no histamine liberation. [15, 22, 23] An early description of 
the safety and efficacy of succinylcholine was reported with self-administration in 1952. The 
author suggested that the drug was safe and could be used to provide muscle relaxation during 
abdominal and thoracic operations, facilitate tracheal intubation, overcome laryngospasm, and be 
used as an adjunct during electroconvulsive therapy. [24] Other case reports in 1952 began to 
draw attention to abnormally long recovery times in some patients, which contradicted 
succinylcholine’s characteristic short duration of action. [25, 26] This alarming adverse effect of 
prolonged apnea was confirmed in large-scale clinical trials in 1953. The explanation proposed at 
the time was that these patients had lower cholinesterase levels, meaning they were unable to 
metabolize succinylcholine at a normal rate. [27-29] The reasoning evolved as it became clear 
that the true problem lay within cholinesterase enzyme activity and abnormalities, and not levels. 
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However, in certain clinical states such as pregnancy and liver disease, low levels of normal 
enzyme too could result in a prolonged block from succinylcholine. 
Myalgia in patients following the administration of another neuromuscular blocker, 
decamethonium, prompted investigations into the possibility of myalgia following 
succinylcholine use in patients. This side effect was briefly mentioned in Bourne’s 1952 
publication, where it was stated that patients who experienced vigorous fasciculations were more 
likely to experience postoperative muscle stiffness. [25] In 1954, Churchill-Davidson conducted 
a trial comparing the rates of muscle pain between patients who received succinylcholine for 
outpatient procedures versus inpatient procedures (i.e. confined to the hospital for at least 48 
hours postoperatively). [30] For the outpatient group, 66% of patients reported generalized 
myalgias and stiffness starting postoperative day one. Only 14% of patients in the inpatient 
procedures group reported myalgia one day after their procedures. Churchill-Davidson attributed 
the difference in the rate of myalgia to the fact that the inpatient group was confined to bedrest 
after succinylcholine use. This report initially didn’t receive much attention but studies followed 
in 1956 and 1957 that reported incidences of postoperative muscle pains from 20 to 70% 
associated with succinylcholine. [31, 32] Numerous trials were conducted through the next 
decades to determine what pharmaceutical agents can help prevent the development of myalgia, 
a side effect that ranged from being a mild nuisance to temporarily debilitating for some patients. 
A meta-analysis of 52 studies by Schreiber et al in 2005 concluded that nonsteroidal anti-
inflammatory drugs (NSAIDs), rocuronium, and lidocaine were most effective at preventing 
myalgia. [33] The meta-analysis also could not establish a correlation between the incidence of 
fasciculations and myalgia, suggesting that they are caused by different mechanisms, and thus an 
agent that prevents fasciculations may not necessarily prevent myalgia.  
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Animal studies conducted in 1960 showed that administration of succinylcholine 
produced a transient increase in plasma potassium, which might have been one of the earliest 
warnings of hyperkalemia caused by succinylcholine. [34] Though earlier studies identified the 
contraindication of succinylcholine in burn patients, which usually resulted in cardiac arrest, the 
mechanism underlying this side effect was undetermined. [35, 36] In 1969, Schaner and 
colleagues performed a series of studies showing that the injection of succinylcholine in burn 
patients, between 20-60 days post-burn, produced hyperkalemia; hyperkalemia increases with 
larger burns and larger doses of succinylcholine and the authors cautioned its use in burn 
patients. [37] In 1973, animal studies demonstrated that denervated muscle, found in burn and 
trauma victims, underwent massive depolarization in response to succinylcholine, which 
increases membrane permeability to potassium, thus contributing to hyperkalemia. [38] 
Another side effect associated with succinylcholine, malignant hyperthermia, began to 
appear in the literature in the late 1960s. In 1966, cases of malignant hyperthermia were 
described in Canada and a warning sign for this side effect was the unexplained muscle rigidity 
that followed succinylcholine administration, especially when combined with halothane. [39, 40] 
More reports followed from Britain, describing similar problems with elevated temperature 
following anesthesia but maintained that the cause was not entirely due to succinylcholine. [41] 
Numerous trials began, aiming to find the etiology of malignant hyperthermia. Denborough and 
colleagues determined that muscle rigidity was due to an increase in free intracellular calcium 
ions, precipitated by an anesthetic agent, and this resulted in persistent muscle contracture with a 
concomitant increase in energy utilization and excess heat production. [42] A breakthrough 
animal study in 1991 revealed that malignant hyperthermia was correlated with a mutation in the 
skeletal muscle ryanodine receptor (RyR1). [43] 
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Minor side effects such as fasciculations and myalgia were reported in the early editions 
of anesthesia textbooks. [44-46] The earliest major side effect reported was prolonged apnea; this 
appeared in textbooks by 1955, three years after initial case reports. [44, 46, 47] Bradycardia was 
mentioned in textbooks starting in 1960, hyperkalemia was discussed starting in 1965, and 
malignant hyperthermia appeared starting in 1970; all lagging a few years behind the original 
case reports since textbooks were only updated every few years. [46, 48-52] Other minor side 
effects were included as textbooks continued to update into the 1970s; these included increased 
intraocular pressure, a small amount of histamine release, a weal and flare production similar to 
that produced by d-tubocurarine administration, tachycardia and other cardiac irregularities, 
hypertension, and cardiovascular collapse. 
Succinylcholine was marketed as “Anectine” by BW Co. Its booklets included 
precautions, contraindications, and warnings as early as 1952-1956 (estimated) about prolonged 
apnea due to plasma-cholinesterase activity, muscle stimulation, and increased intraocular 
pressure that cautions use in intraocular surgery. (Figures 1-3) BW Co.’s 1952 Anectine 
booklet’s “Contraindications and Precautions” section warns against fasciculations and 
prolonged apnea. (Figure 1) Another Anectine booklet from 1954 includes a “Side Effects” 
section, which describes fasciculations as the only significant side effect. (Figure 2) A double-
sided booklet insert from 1955 describes fasciculations as a side effect but otherwise notes that 
succinylcholine has “no toxic side effects”, though it is unclear if the lack of side effects 
included on this advertisement is due to text constraints or a deliberate marketing decision. 
Single-paged advertisements in journals such as Anesthesiology and Anesthesia & Analgesia 
boasted succinylcholine’s rapid acting properties but did not list side effects. (Figures 4-5) BW 
Co.’s own updated booklet in 1962 emphasized that succinylcholine had “virtually no toxicity; 
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virtually no side effects” in the beginning of the packet before listing prolonged apnea, 
fasciculations, and increased intraocular pressure under its “Contraindications and Precautions” 
section. (Figure 6) These warnings of adverse effects remained in other promotional material and 
only increased in number and detail. BW Co.’s 1975 booklet about Anectine included warnings 
about bradycardia, myalgia, malignant hyperthermia and hyperkalemia. (Figure 7) These side 
effects were not listed in the 1965 versions of the promotional material. Table 1 lists the 
appearance of complications in journals, textbooks in anesthesiology, and drug package inserts. 
Documents submitted to the FDA from 1971 to 1973 by BW Co. provided some details 
pertaining to sterility and potency problems of the original packaging and reflected new 
information about toxicity. (Figure 8) The company also delayed sending current manufacturing 
information, prompting several reminders from the FDA. The application was initially marked 
incomplete since BW Co. did not include full reports of adequate Limulus Amebocyte Lysate 
testing, an endotoxin test required of all pharmaceuticals and devices that come in contact with 
blood of cerebrospinal fluid. The package insert updates were approved in December 1975, 
which included warnings of malignant hyperthermia and hyperkalemia in burn patients. (Figure 
9) Other FDA documents noted that the resubmission of these applications “has been lengthy” 
and mostly due to insufficient data provided by the manufacturer. These documents point out 
that the company had been marketing succinylcholine (Flo-Pack) without an approved 
supplement for sterilization, and there was no specific mention about the suppression of known 
side effects. In 1981, during another package insert revision, the FDA made amendments to 
several sections, including the expansion of succinylcholine’s list of contraindications and 
required an entire section devoted to malignant hyperthermia. These warnings remained on the 
package inserts, which continue to be revised and resubmitted as late as 2010. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Discussion  
D-tubocurarine enjoyed a short period of popularity before case reports suggested several 
side effects related to histamine release – hypotension, bradycardia, bronchospasm, and 
increased salivary secretions. Updated textbook editions reflected these details, but 
advertisements and promotional materials were slow to include these side effects. It is unclear 
whether this was due to limitations in the size of the advertisement, or if the manufacturers did 
not include negative effects.  
Efforts to replace d-tubocurarine may have resulted in the development of 
succinylcholine. Scientists set out to synthesize a new anesthetic that mimicked the structure of 
d-tubocurarine. One of these compounds was decamethonium and it was theorized that its 
success was due to a 10-atom distance between its two nitrogen atoms. Succinylcholine, once 
called diacetycholine, was synthesized with the same goal of a 10-atom distance between its 
nitrogen atoms, and its structure resembled two acetylcholine molecules laid end to end, giving it 
depolarizing neuromuscular blocking properties. Succinylcholine became a very popular choice 
of muscle relaxant due to its rapid onset and short duration as a result of its rapid breakdown in 
the body. It replaced d-tubocurarine as the relaxant of choice for tracheal intubation and short 
surgical procedures. D-tubocurarine continued to be used for longer operations.  
The regulations surrounding drug development and marketing evolved during the same 
time succinylcholine was synthesized and manufactured. Succinylcholine was manufactured and 
marketed with a clear purpose on its labels, and with instruction to be used by medical 
professionals only. In compliance with the voluntary program to report drug reactions, 
researchers documented any side effect they thought were attributed to succinylcholine use in 
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their case reports. Following the Kefauver-Harris Amendments of 1962, reports continued to be 
published of new side effects despite succinylcholine’s widespread market penetration by then. 
We found that BW Co. updated their packaging and marketing material to reflect new side 
effects and warnings, in line with the Fair Packaging and Labeling Act of 1966 and we found 
evidence the form of FDA documents of BW Co. updating their drug package inserts in 1970. 
Though it appears that BW Co. was slow at providing the required documents to the FDA and 
delayed the application, the manufacturer was compliant in updating its marketing and packaging 
material with new side effects in an appropriate manner. 
Despite its shortcomings and well-documented side effects in promotional materials and 
package inserts, succinylcholine survives to this day in the U.S., unlike halothane and d-
tubocurarine. Anesthesiologists still prefer its quick onset and short duration properties. Not 
surprisingly, this has prompted a search for new compounds that have the same action as 
succinylcholine without the side effects. Although newer agents may possess the ability to 
provide muscle relaxation quite rapidly, they suffer from prolonged duration of blockade. A 
recent development has been the introduction of a reversal agent sugammadex. This drug binds 
to steroid neuromuscular blockers such as rocuronium and vecuronium and inactivates them 
rapidly. Thus, in a roundabout manner, two agents administered in series can deliver the 
advantages offered by succinylcholine. A clinical trial compared the recovery time of 
rocuronium and sugammadex (to reverse the neuromuscular block) to succinylcholine; and found 
that of the rocuronium/sugammadex combination was shorter. [53, 54] However, sugammadex 
too is associated with side effects, including rare anaphylactic reactions. [55] Thus, it remains to 
be seen if this combination will successfully replace this long-standing muscle relaxant. We can 
look forward to newer relaxants to replace succinylcholine. 
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Conclusions  
Anesthetic medications are bound to the same lifecycle as any other medication or 
consumer product. Their introduction, built upon years and decades of investigative efforts, 
fulfilled a specific niche in anesthesia and the relatively unregulated medical market allowed 
easy dissemination of the product to clinicians and researchers. These medications enjoyed great 
popularity during their early years as clinicians were eager to try drugs with novel properties. 
With broader use, some effects of the drugs that were previously undetected appeared. Initial 
single reports are often insufficient to influence the majority opinion but as more cases are 
reported, particularly when those with lethal outcomes capture the spotlight, further 
investigations, updated with the constantly growing knowledge of the medical field, are 
warranted to look for toxicity. Often, researchers choose to abandon the drug at this stage and 
look for better alternatives, but succinylcholine had too many clinical advantages to abandon it. 
The manufacturer amended the package insert and advertisements to warn against 
contraindications and adverse effects. Textbooks and other authoritative sources on 
pharmaceuticals also updated each edition to reflect additional side effects. Typically, by this 
time, clinicians become wary of the undesired outcomes of even those drugs with unique 
properties and moved on to other options. So, new clinical guidelines for succinylcholine were 
issued. Replacement drugs were and are continuing to be developed; the next few decades could 
present a new clinically relevant depolarizing muscle relaxant. 
It’s difficult to say whether or not there will one day be a drug that will stay in use 
forever. The lifecycle of a medication seems to indicate that we will discover and confirm the 
adverse effects of drugs once they have widespread use and then move on to a better alternative. 
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As long as there is a need to improve pharmacological agents, there will be a drive for new 
discoveries.  
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Figure 1. BWC Anectine booklet, 1952 (estimated), pages 1 and 3 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure 2. BWC Anectine booklet, 1954 (estimated), cover and side effects section 
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Figure 3. BWC Anectine booklet 1955 (estimated) 
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Figure 4. A 1955 advertisement in Anesthesiology 
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Figure 5. A 1957 advertisement in Anesthesia & Analgesia  
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Figure 6. A 1962 BWC Anectine booklet, pages 3-6 
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Figure 7. A 1975 BWC Anectine booklet, pages 7-9 
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Figure 8. 1972 FDA document 
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Figure 9. 1975 FDA document 
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Table 1. The year of appearance of select adverse effects of succinylcholine in journals, textbooks 
in anesthesiology, and drug package inserts. 
Adverse 
reaction 
Year when adverse reaction appeared in 
literature 
Year when adverse reaction appeared 
in different textbooks 
Year when adverse reaction appeared in drug 
company literature 
Bradycardia *1952 – Thesleff S. The pharmacological 
properties of succinylcholine iodide; with 
particular reference to its clinical use as a 
muscular relaxant. Acta Physiol Scand. 
1952;26:103-29. 
 
1957 – Leigh MD, McCoy DD, Belton MK, 
Lewis GB. Bradycardia following 
intravenous administration of 
succinylcholine chloride to infants and 
children. Anesthesiology. 1957;18:698-702. 
 
1958 – Martin KH. International 
Symposium on Curare and Curare-like 
Drugs. Atti XI Congresso Societa Italiana 
de Anestesiologia, Venezia. September 
1958, p. 362. 
 
1959 – Bullough J. Intermittent 
Suxamethonium Injections. Br Med J. 
1959;1:786-787. 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
 
1965 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
3rd ed. New York: The Macmillan 
Company; 1965. 
 
1966 – Collins VJ. Principles of 
Anesthesiology. Philadelphia: Lea & 
Febiger; 1966. 
 
1967 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
3rd ed. Philadelphia: WB Saunders 
Company; 1967.  
 
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Actions” and “Adverse 
Reactions” sections. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
Fasciculations 1952 – Thesleff S. The pharmacological 
properties of succinylcholine iodide; with 
particular reference to its clinical use as a 
muscular relaxant. Acta Physiol Scand. 
1952;26:103-29. 
 
1952 – Butt NS. A report on the use of 
succinylcholine chloride in a thoracic unit. 
Br J Anaesth. 1952;24:245-51. 
 
1952 – Foldes FF, McNall PG, Borrego-
Hinojosa JM. Succinylcholine: a new 
approach to muscular relaxation in 
anesthesiology. N Engl J Med. 
1952;247:596-600. 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
 
1961 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
2nd ed. Philadelphia: WB Saunders 
Company; 1961.  
 
1965 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
3rd ed. New York: The Macmillan 
Company; 1965. 
 
1966 – Collins VJ. Principles of 
Anesthesiology. Philadelphia: Lea & 
Febiger; 1966. 
 
1952 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Contraindications 
and Precautions” section. 
 
1954 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Side Effects” 
section. 
 
1962 – Burroughs Wellcome and Company 
“Anectine” booklet, “Contraindications and 
Precautions” section. 
 
Myalgia 1952 – Bourne JG, Collier HO, Somers GF. 
Succinylcholine (succinoylcholine) muscle-
relaxant of short action. Lancet. 
1952;259(6721):1225-9. 
 
1954 – Churchill-Davidson HC. 
Suxamethonium (succinylcholine) chloride 
1955 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
2nd ed. New York: The Macmillan 
Company; 1955. 
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Actions” and “Adverse 
Reactions” sections. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
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and muscle pains. Br Med J. 
1954;1(4853):74. 
 
1956 – Hegarty P. Postoperative muscle 
pains. Br J Anaesth. 1956;28(5):209-12. 
Luke; 1960. 
 
1961 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
2nd ed. Philadelphia: WB Saunders 
Company; 1961.  
 
Prolonged apnea 1952 – Bourne JG, Collier HO, Somers GF. 
Succinylcholine (succinoylcholine), muscle-
relaxant of short action. Lancet. 
1952;1:1225-9. 
 
1952 – Evans FT, Gray PW, Lehmann H, 
Silk E. Sensitivity to succinylcholine in 
relation to serum-cholinesterase. Lancet. 
1952;259(6721):1229-30. 
 
1953 – Bourne, JG. Long action of 
suxamethonium (succinylcholine) chloride. 
Br J Anaesth. 1953;25:116-29. 
 
1953 – Forbat A, Lehmann H, Silk E. 
Prolonged apnoea following injection of 
succinyldicholine. Lancet. 
1953;262(6795):1066-8. 
 
1955 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
2nd ed. New York: The Macmillan 
Company; 1955. 
 
1957 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
1st ed. Philadelphia: WB Saunders 
Company; 1957.  
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
 
1961 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
2nd ed. Philadelphia: WB Saunders 
Company; 1961.  
1952 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Contraindications 
and Precautions” section. 
 
1962 – Burroughs Wellcome and Company 
“Anectine” booklet, “Contraindications and 
Precautions” section. 
 
Hyperkalemia 1960 – Stevenson D. Changes in the blood 
electrolytes of anaesthetized dogs caused by 
suxamethonium. Br J Anaesth. 
1960;32:364-71.  
 
1962 – Bush GH, Graham HA, Littlewood 
AH, Scott LB. Danger of suxamethonium 
and endotracheal intubation in anaesthesia 
for burns. Br Med J. 1962;2:1081-5. 
 
1963 – McCaughey TJ. Burn Mortality and 
the Anaesthetist. Can Anaesth Soc J. 
1963;10:501-7. 
 
1969 – Schaner PJ, Brown RL, Kirksey TD, 
Gunther RC, Ritchey CR, Gronert GA. 
Succinylcholineinduced hyperkalemia in 
burned patients. 1. Anesth Analg. 
1969;48:764-70  
1965 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
3rd ed. New York: The Macmillan 
Company; 1965. 
 
1967 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
3rd ed. Philadelphia: WB Saunders 
Company; 1967.  
 
1976 – Collins VJ. Principles of 
Anesthesiology. 2nd ed. Philadelphia: Lea 
& Febiger; 1976.  
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Precautions” section. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
Malignant 
hyperthermia 
1966 – Thut WH, Davenport HT. 
Hyperpyrexia associated with 
succinylcholine-induced muscle rigidity: a 
case report. Can Anaesth Soc J. 
1966;13:425-8 
 
1970 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
4th ed. New York: The Macmillan 
Company; 1970. 
 
1976 – Collins VJ. Principles of 
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Precautions” section. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
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1969 – Murray BR, Williams PA. 
Malignant hyperpyrexia during anaesthesia 
for colectomy. Br Med J. 1969;1:488 
 
1980 – Denborough MA. The 
pathopharmacology of malignant 
hyperpyrexia. Pharmacol Ther. 1980;9:357-
65 
Anesthesiology. 2nd ed. Philadelphia: Lea 
& Febiger; 1976. 
 
*In doses >30mg/kg (animal studies) 
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Table 1. The year of appearance of select adverse effects of succinylcholine in journals, textbooks 
in anesthesiology, and drug package inserts. 
Adverse 
reaction 
Year when adverse reaction appeared in 
literature 
Year when adverse reaction appeared 
in different textbooks 
Year when adverse reaction appeared in drug 
company literature 
Bradycardia *1952 – Thesleff S. The pharmacological 
properties of succinylcholine iodide; with 
particular reference to its clinical use as a 
muscular relaxant. Acta Physiol Scand. 
1952;26:103-29. 
 
1957 – Leigh MD, McCoy DD, Belton MK, 
Lewis GB. Bradycardia following 
intravenous administration of 
succinylcholine chloride to infants and 
children. Anesthesiology. 1957;18:698-702. 
 
1958 – Martin KH. International 
Symposium on Curare and Curare-like 
Drugs. Atti XI Congresso Societa Italiana 
de Anestesiologia, Venezia. September 
1958, p. 362. 
 
1959 – Bullough J. Intermittent 
Suxamethonium Injections. Br Med J. 
1959;1:786-787. 
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
 
1965 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
3rd ed. New York: The Macmillan 
Company; 1965. 
 
1966 – Collins VJ. Principles of 
Anesthesiology. Philadelphia: Lea & 
Febiger; 1966. 
 
1967 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
3rd ed. Philadelphia: WB Saunders 
Company; 1967.  
 
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Actions” and “Adverse 
Reactions” sections. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
Fasciculations 1952 – Thesleff S. The pharmacological 
properties of succinylcholine iodide; with 
particular reference to its clinical use as a 
muscular relaxant. Acta Physiol Scand. 
1952;26:103-29. 
 
1952 – Butt NS. A report on the use of 
succinylcholine chloride in a thoracic unit. 
Br J Anaesth. 1952;24:245-51. 
 
1952 – Foldes FF, McNall PG, Borrego-
Hinojosa JM. Succinylcholine: a new 
approach to muscular relaxation in 
anesthesiology. N Engl J Med. 
1952;247:596-600. 
 
1955 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
2nd ed. New York: The Macmillan 
Company; 1955. 
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
 
1961 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
2nd ed. Philadelphia: WB Saunders 
Company; 1961.  
1952 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Contraindications 
and Precautions” section. 
 
1954 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Side Effects” 
section. 
 
1962 – Burroughs Wellcome and Company 
“Anectine” booklet, “Contraindications and 
Precautions” section. 
 
Myalgia 1952 – Bourne JG, Collier HO, Somers GF. 
Succinylcholine (succinoylcholine) muscle-
relaxant of short action. Lancet. 
1952;259(6721):1225-9. 
 
1954 – Churchill-Davidson HC. 
Suxamethonium (succinylcholine) chloride 
and muscle pains. Br Med J. 
1955 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
2nd ed. New York: The Macmillan 
Company; 1955. 
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Actions” and “Adverse 
Reactions” sections. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
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1954;1(4853):74. 
 
1956 – Hegarty P. Postoperative muscle 
pains. Br J Anaesth. 1956;28(5):209-12. 
 
1961 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
2nd ed. Philadelphia: WB Saunders 
Company; 1961.  
 
Prolonged apnea 1952 – Bourne JG, Collier HO, Somers GF. 
Succinylcholine (succinoylcholine), muscle-
relaxant of short action. Lancet. 
1952;1:1225-9. 
 
1952 – Evans FT, Gray PW, Lehmann H, 
Silk E. Sensitivity to succinylcholine in 
relation to serum-cholinesterase. Lancet. 
1952;259(6721):1229-30. 
 
1953 – Bourne, JG. Long action of 
suxamethonium (succinylcholine) chloride. 
Br J Anaesth. 1953;25:116-29. 
 
1953 – Forbat A, Lehmann H, Silk E. 
Prolonged apnoea following injection of 
succinyldicholine. Lancet. 
1953;262(6795):1066-8. 
 
1955 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
2nd ed. New York: The Macmillan 
Company; 1955. 
 
1957 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
1st ed. Philadelphia: WB Saunders 
Company; 1957.  
 
1960 – Wylie WD, Davidson HCC. A 
Practice of Anaesthesia. London: Lloyd-
Luke; 1960. 
1952 (estimated) – Burroughs Wellcome and 
Company “Anectine” booklet, “Contraindications 
and Precautions” section. 
 
1962 – Burroughs Wellcome and Company 
“Anectine” booklet, “Contraindications and 
Precautions” section. 
 
Hyperkalemia 1960 – Stevenson D. Changes in the blood 
electrolytes of anaesthetized dogs caused by 
suxamethonium. Br J Anaesth. 
1960;32:364-71.  
 
1962 – Bush GH, Graham HA, Littlewood 
AH, Scott LB. Danger of suxamethonium 
and endotracheal intubation in anaesthesia 
for burns. Br Med J. 1962;2:1081-5. 
 
1963 – McCaughey TJ. Burn Mortality and 
the Anaesthetist. Can Anaesth Soc J. 
1963;10:501-7. 
 
1969 – Schaner PJ, Brown RL, Kirksey TD, 
Gunther RC, Ritchey CR, Gronert GA. 
Succinylcholineinduced hyperkalemia in 
burned patients. 1. Anesth Analg. 
1969;48:764-70  
 
1965 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
3rd ed. New York: The Macmillan 
Company; 1965. 
 
1967 – Dripps RD, Eckenhoff JE, 
Vandam LD. Introduction to Anesthesia. 
3rd ed. Philadelphia: WB Saunders 
Company; 1967.  
 
1976 – Collins VJ. Principles of 
Anesthesiology. 2nd ed. Philadelphia: Lea 
& Febiger; 1976.  
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Precautions” section. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
Malignant 
hyperthermia 
1966 – Thut WH, Davenport HT. 
Hyperpyrexia associated with 
succinylcholine-induced muscle rigidity: a 
case report. Can Anaesth Soc J. 
1966;13:425-8 
 
1970 – Goodman LS, Gillman A. The 
Pharmacological Basis of Therapeutics. 
4th ed. New York: The Macmillan 
Company; 1970. 
 
1976 – Collins VJ. Principles of 
1975 – Burroughs Wellcome and Company 
“Anectine” booklet, “Precautions” section. 
 
1975 – Burroughs Wellcome and Company’s 
“Anectine” FDA document approval 
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1969 – Murray BR, Williams PA. 
Malignant hyperpyrexia during anaesthesia 
for colectomy. Br Med J. 1969;1:488 
 
1980 – Denborough MA. The 
pathopharmacology of malignant 
hyperpyrexia. Pharmacol Ther. 1980;9:357-
65 
Anesthesiology. 2nd ed. Philadelphia: Lea 
& Febiger; 1976. 
 
*In doses >30mg/kg (animal studies) 
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Succinylcholine, a depolarizing neuromuscular blocker, was introduced into clinical practice in 
1953. 
 
It was associated with hyperkalemia and malignant hyperthermia.  
 
These potential side effects were not known to the manufacturer when the drug was introduced. 
 
We found no evidence that Burroughs Wellcome and Company, New York [the manufacturer] 
suppressed information about these side effects.  
 
After several decades of clinical use, succinylcholine continues to be used throughout the world, 
although newer neuromuscular blockers and reversal agents may affect its popularity.  
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